Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Baird Cuts Price Target on Enanta Pharma (ENTA) Despite Bottom-Line Beat
February 9, 2016 7:28 AM ESTBaird remains Neutral on Enanta Pharmaceuticals (NASDAQ: ENTA), and cut the price target to $22.00 (from $36.00), following the company's 1Q. Non-GAAP EPS was reported at $1.36, beating consensus estimates of $1.13. The company ended the quarter with $236.6M in cash, which management expects will last for the... More
Enanta Pharma (ENTA) Tops Q1 EPS by 23c
February 8, 2016 4:05 PM ESTEnanta Pharma (NASDAQ: ENTA) reported Q1 EPS of $1.36, $0.23 better than the analyst estimate of $1.13. Revenue for the quarter came in at $48.4 million versus the consensus estimate of $47.05 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
... More